DexCom announced what it called “a significant advancement in access to its products for those treating Type 2 diabetes, or T2D, with basal insulin injections” as the company has secured access to its Dexcom ONE sensor for around 100,000 T2D users in France. “The reimbursement guidance offers people aged over two years who are on non-intensified insulin therapy and whose glycaemic control is insufficient access to Dexcom’s life-changing technology. The French government is the first in Europe to offer full national reimbursement for Dexcom CGM technology to those treating T2D with basal injections, following other countries around the world such as the USA and New Zealand,” the company stated.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- PayPal upgraded, UiPath downgraded: Wall Street’s top analyst calls
- DexCom initiated with a Neutral at Redburn Atlantic
- DexCom participates in a conference call with JPMorgan
- ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
- DexCom price target raised to $160 from $151 at Raymond James